126 related articles for article (PubMed ID: 8035983)
1. Effects of intraocular bubble duration in the treatment of macular holes by vitrectomy and transforming growth factor-beta 2.
Thompson JT; Glaser BM; Sjaarda RN; Murphy RP; Hanham A
Ophthalmology; 1994 Jul; 101(7):1195-200. PubMed ID: 8035983
[TBL] [Abstract][Full Text] [Related]
2. Intraocular tamponade duration and success of macular hole surgery.
Thompson JT; Smiddy WE; Glaser BM; Sjaarda RN; Flynn HW
Retina; 1996; 16(5):373-82. PubMed ID: 8912962
[TBL] [Abstract][Full Text] [Related]
3. The results of vitreous surgery for chronic macular holes.
Thompson JT; Sjaarda RN; Lansing MB
Retina; 1997; 17(6):493-501. PubMed ID: 9428011
[TBL] [Abstract][Full Text] [Related]
4. Increased intraocular pressure after macular hole surgery.
Thompson JT; Sjaarda RN; Glaser BM; Murphy RP
Am J Ophthalmol; 1996 Jun; 121(6):615-22. PubMed ID: 8644803
[TBL] [Abstract][Full Text] [Related]
5. SULFURHEXAFLUORIDE (SF6) VERSUS PERFLUOROPROPANE (C3F8) GAS AS TAMPONADE IN MACULAR HOLE SURGERY.
Modi A; Giridhar A; Gopalakrishnan M
Retina; 2017 Feb; 37(2):283-290. PubMed ID: 28118283
[TBL] [Abstract][Full Text] [Related]
6. Comparison of recombinant transforming growth factor-beta-2 and placebo as an adjunctive agent for macular hole surgery.
Thompson JT; Smiddy WE; Williams GA; Sjaarda RN; Flynn HW; Margherio RR; Abrams GW
Ophthalmology; 1998 Apr; 105(4):700-6. PubMed ID: 9544645
[TBL] [Abstract][Full Text] [Related]
7. The effect of pars plana vitrectomy and transforming growth factor-beta 2 without epiretinal membrane peeling on full-thickness macular holes.
Lansing MB; Glaser BM; Liss H; Hanham A; Thompson JT; Sjaarda RN; Gordon AJ
Ophthalmology; 1993 Jun; 100(6):868-71; discussion 871-2. PubMed ID: 8510899
[TBL] [Abstract][Full Text] [Related]
8. Progression of nuclear sclerosis and long-term visual results of vitrectomy with transforming growth factor beta-2 for macular holes.
Thompson JT; Glaser BM; Sjaarda RN; Murphy RP
Am J Ophthalmol; 1995 Jan; 119(1):48-54. PubMed ID: 7825689
[TBL] [Abstract][Full Text] [Related]
9. Surgical management of macular holes: results using gas tamponade alone, or in combination with autologous platelet concentrate, or transforming growth factor beta 2.
Minihan M; Goggin M; Cleary PE
Br J Ophthalmol; 1997 Dec; 81(12):1073-9. PubMed ID: 9497468
[TBL] [Abstract][Full Text] [Related]
10. Vitrectomy, fluid-gas exchange and transforming growth factor--beta-2 for the treatment of traumatic macular holes.
Rubin JS; Glaser BM; Thompson JT; Sjaarda RN; Pappas SS; Murphy RP
Ophthalmology; 1995 Dec; 102(12):1840-5. PubMed ID: 9098285
[TBL] [Abstract][Full Text] [Related]
11. Gas injection versus vitrectomy with gas for treating retinal detachment owing to macular hole in high myopes.
Li X; Wang W; Tang S; Zhao J
Ophthalmology; 2009 Jun; 116(6):1182-87.e1. PubMed ID: 19375168
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of sulfur hexafluoride (SF6) versus perfluoropropane (C3F8) gas tamponade for macular hole surgery.
Kim SS; Smiddy WE; Feuer WJ; Shi W
Retina; 2008; 28(10):1408-15. PubMed ID: 18827734
[TBL] [Abstract][Full Text] [Related]
13. Prospective randomized trial of vitrectomy or observation for stage 2 macular holes. Vitrectomy for Macular Hole Study Group.
Kim JW; Freeman WR; Azen SP; el-Haig W; Klein DJ; Bailey IL
Am J Ophthalmol; 1996 Jun; 121(6):605-14. PubMed ID: 8644802
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant methods in macular hole surgery: intraoperative plasma-thrombin mixture and postoperative fluid-gas exchange.
Blumenkranz MS; Ohana E; Shaikh S; Chang S; Coll G; Morse LS; De Bustros S
Ophthalmic Surg Lasers; 2001; 32(3):198-207. PubMed ID: 11371086
[TBL] [Abstract][Full Text] [Related]
15. Pars plana vitrectomy and perfluoropropane (C3F8) tamponade for retinal detachment due to myopic macular hole: a prognostic factor analysis.
Lam RF; Lai WW; Cheung BT; Yuen CY; Wong TH; Shanmugam MP; Lam DS
Am J Ophthalmol; 2006 Dec; 142(6):938-44. PubMed ID: 17157579
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of outpatient fluid-gas exchange for open macular hole after vitrectomy.
Rao X; Wang NK; Chen YP; Hwang YS; Chuang LH; Liu IC; Chen KJ; Wu WC; Lai CC
Am J Ophthalmol; 2013 Aug; 156(2):326-333.e1. PubMed ID: 23688710
[TBL] [Abstract][Full Text] [Related]
17. Surgical treatment of macular holes with multiple recurrences.
Thompson JT; Sjaarda RN
Ophthalmology; 2000 Jun; 107(6):1073-7. PubMed ID: 10857825
[TBL] [Abstract][Full Text] [Related]
18. Transforming growth factor-beta 2 for the treatment of full-thickness macular holes. A prospective randomized study.
Glaser BM; Michels RG; Kuppermann BD; Sjaarda RN; Pena RA
Ophthalmology; 1992 Jul; 99(7):1162-72; discussion 1173. PubMed ID: 1495798
[TBL] [Abstract][Full Text] [Related]
19. Vitrectomy without face-down posturing for idiopathic macular holes.
Nadal J; Delas B; Piñero A
Retina; 2012 May; 32(5):918-21. PubMed ID: 22080914
[TBL] [Abstract][Full Text] [Related]
20. Fluorescein angiographic characteristics of macular holes before and after vitrectomy with transforming growth factor beta-2.
Thompson JT; Hiner CJ; Glaser BM; Gordon AJ; Murphy RP; Sjaarda RN
Am J Ophthalmol; 1994 Mar; 117(3):291-301. PubMed ID: 8129001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
